

Comparison between steroids taken by mouth and steroids administered by lumbar epidural for sciatica pain

Submission date 11/02/2021	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 24/03/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/02/2021	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Sciatica refers to back pain caused by a problem with the sciatic nerve. This is a large nerve that runs from the lower back down the back of each leg. When something injures or puts pressure on the sciatic nerve, it can cause pain in the lower back that spreads to the hip, buttocks, and leg. The objective of the present study will be to compare the effectiveness of the medications of the systemic corticosteroids class in relation to lumbar infiltrations in the relief of sciatica caused by lumbar disc herniation.

Who can participate?

Patients with severe sciatica, with recent onset, being followed up at the Spine Surgery outpatient clinic at Hospital São Paulo and Hospital Municipal de Barueri

What does the study involve?

Patients will be drawn in two groups in relation to the treatment they will be submitted for pain relief and resumption of function. It is important to highlight that both treatments are routinely performed in this clinic and participation in the study does not increase the risk of therapy failure in resolving the clinical condition. In the first approach, an initial interview will be carried out and protocols filled out that seek to measure the intensity of the pain that the patient presents, as well as pertinent imaging exams will be requested if the patient does not have them. After 1 week of the initial care, the intervention will be performed, according to the group for which the patient was drawn. These correspond:

- Group 1: The participants of this group will be submitted to transforaminal epidural infiltration, with corticosteroids and analgesics of local action, performed in a surgical environment under sedation. In summary, the participant will be instructed to be admitted to the hospital on the same day of the procedure, fasting at least 8 hours. In the operating room, the participant will be in prone position (lying on his stomach) and, after medication to sedate and relieve the pain of the procedure, the researcher will perform the procedure, lasting about 20 minutes. After recovery from anesthesia, with about 3 hours, the participant will be discharged from hospital with the appropriate guidelines.
- Group 2: Participants in this group will undergo treatment with oral medications for 3 weeks,

these being 20mg prednisone, according to medical prescription.
After treatment, the participant will be reassessed in 3 weeks and 6 weeks after the intervention, in the same outpatient clinic where initial care was performed and, on this occasion, the pain and function forms will be reapplied in order to measure the improvement in pain and function obtained. with each treatment.

What are the possible benefits and risks of participating?

The main benefits of participating in the research include mainly the contribution to optimize the treatment of cases similar to yours, aiming at improving the indication of each one of them in the case of acute sciatica. For the participant, the main benefit is the relief of pain and improvement of the clinical condition and function, since both treatments are effective in resolving symptoms.

Each treatment modality has inherent risks, with low rates of probability of occurrence.

Where is the study run from?

1. Hospital São Paulo (Brazil)
2. Hospital Municipal de Barueri (Brazil)

When is the study starting and how long is it expected to run for?

September 2020 to July 2022

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Prof Marcel Tamaoki, marceltamaoki@gmail.com

Guilherme Porceban, gporceban@gmail.com

Renato Ueta, uetarenato@gmail.com

Study website

<https://redcap.epm.br/surveys/?s=8M8ADPE8C9>

Contact information

Type(s)

Scientific

Contact name

Prof Marcel Tamaoki

ORCID ID

<https://orcid.org/0000-0002-9539-4545>

Contact details

St. Borges Lagoa, 786

Vila Clementino

São Paulo

Brazil

04038002

+55(11) 55797049

marcel.tamaoki@unifesp.br

Type(s)

Public

Contact name

Mr Guilherme Porceban

ORCID ID

<https://orcid.org/0000-0002-5431-166X>

Contact details

Av Onze de Junho, 1266. Apto 44

São Paulo

Brazil

04041004

+55(16)982007111

gporceban@gmail.com

Type(s)

Public

Contact name

Mr Renato Ueta

ORCID ID

<https://orcid.org/0000-0002-3458-0184>

Contact details

St. Borges Lagoa, 786

Vila Clementino

São Paulo

Brazil

04038002

+55(16)982007111

uetarenato@gmail.com

Additional identifiers**EudraCT/CTIS number**

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Ethics number: 4.460.808

Study information

Scientific Title

Lumbar transforaminal epidural injection versus systemic corticosteroids for the treatment of acute sciatica: a randomized clinical trial

Acronym

TEISC

Study objectives

Our hypothesis is that systemic administration of oral corticosteroids is equivalent to periradicular transforaminal infiltrations in relation to improvement of pain and function in patients with higher intensity acute sciatica (Oswestry index greater than 40). Thus, if proven, the prescription of these medications may constitute a less invasive and more accessible option in the treatment of these patients. On the other hand, if the hypothesis is rejected, the systemic prescription of these medications can be reconsidered in view of the side effects associated with this medication class.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved in 14/12/2020, Research Ethics Committee of Federal University of São Paulo (Botucatu St., 740, 5 floor - CEP: 04023-900 - São Paulo-SP, Brazil; +55(11)5571-1062; no email provided), ref: 4.460.808

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Treatment for acute sciatica pain due to lumbar disc herniation

Interventions

This is a prospective randomized clinical trial developed at the Orthopedics-Column outpatient clinic of Hospital São Paulo (EPM / UNIFESP) and its affiliated Hospital Municipal de Barueri. Individuals with a clinical condition compatible with acute sciatica secondary to lumbar disc

herniation are randomly allocated into 2 groups regarding the treatment of choice. The randomization is realized in the randomization module of RedCap database.

- Group 1: the participants of this group will be submitted to transforaminal lumbar epidural infiltration in the week following the initial care. Transforaminal epidural infiltrations are performed using aseptic technique in the operating room. After confirmation of the appropriate location in the foramen through fluoroscopy, 1 ml of iodinated contrast is injected to identify the emerging root. If the desired image is visualized, a solution containing 2.5 ml of analgesics with local action and 2.5 ml of particulate corticosteroids will be administered.

- Group 2: participants in this group will be treated with oral prednisone starting in the week following the initial treatment. The medication used is prednisone, a synthetic corticosteroid with low mineralocorticoid activity. The total dose accumulated in the treatment cycle is 650mg, capable of promoting anti-inflammatory effects without immunosuppression. In addition, this dose has a low risk of suppression of the hypothalamic-adrenal axis, considering that the total treatment time will not exceed 3 weeks.

Intervention Type

Procedure/Surgery

Primary outcome measure

Oswestry Disability Index measured at baseline, 21 days and 60 days.

Secondary outcome measures

1. Pain measured using visual analogue scale at baseline, 21 days and 60 days
2. Presence of neurological deficits - measurement of muscle strength (Global Strength Index, recommended by the Medical Research Council) and tactile sensitivity test compared to the contralateral side (as recommended in the sensitivity measurement protocols) at baseline, 21 days and 60 days

Overall study start date

01/09/2020

Completion date

01/07/2022

Eligibility

Key inclusion criteria

1. Age over 18 years and who accepted to participate in the research by signing the Informed Consent Form
2. Symptoms suggestive of acute sciatica such as low back pain radiating to the lower limbs respecting the specific limits of the lumbar dermatomes and physical examination showing signs of root irritation to the tensioning maneuvers
3. Minimum duration of symptoms greater than 72 hours
4. Maximum duration of symptoms less than 4 weeks
5. Oswestry Disability Index with a score greater than 30 points
6. Imaging exams (radiographs and magnetic resonance) compatible with the clinical picture presented by the patients

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

100

Key exclusion criteria

1. Refusal to sign the Informed Consent Form (ICF)
2. Patients who do not use medications and follow the guidelines of the research team
3. Patients with a clinical condition that requires immediate surgical intervention (for example, cauda equina syndrome)
4. Patients with a previous history of neoplasms or previous trauma (fractures or dislocations) in the spine
5. Patients with a previous history of spinal surgery
6. Patients with comorbidities that indicate chronic use of corticosteroids (autoimmune diseases, conditions of atopy) or that contraindicate the use of this medication class at any time (for example, type 2 diabetes mellitus, uncontrolled systemic arterial hypertension in the last month, pregnancy/puerperium, active peptic ulcer)
7. Previous history of allergy or intolerance to analgesics with local action and/or iodinated components used in TFEI

Date of first enrolment

15/12/2021

Date of final enrolment

31/12/2021

Locations**Countries of recruitment**

Brazil

Study participating centre

Paulista Medical School - Federal University Of São Paulo

St. Botucatu, 740

Vila Clementino

São Paulo - SP

Brazil

04023062

Sponsor information

Organisation

Federal University of Sao Paulo

Sponsor details

St. Sena Madureira, 1500

Vila Clementino

São Paulo

Brazil

04021-001

+55(11) 3385-4100

cep@unifesp.br

Sponsor type

University/education

Website

<http://www.unifesp.br/>

ROR

<https://ror.org/02k5swt12>

Funder(s)**Funder type**

Other

Funder Name

Investigator initiated and funded

Results and Publications**Publication and dissemination plan**

Planned publication in a high-impact peer-review journal.

The participant will have full access to the image exams performed and the total score in the forms predictive of pain and function that will be filled out. At the end of the research and publication of the results, the participants will have information about the data obtained and, consequently, their contribution to the improvement of the treatment of acute sciatica secondary to lumbar disc herniation .

Intention to publish date

01/07/2022

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository (redcap.epm.br) and will be available upon request for the

authors. All the procedures and sociodemographic, clinical and procedures will be available for researchers who provide a methodologically sound proposal. The participant identification data are available only for the main author. In the initial interview, all the participants will be oriented about the sharing of his data and the agreement will be registered by the ICF. The dataset also will be publically available in the subsequent results publication.

IPD sharing plan summary

Stored in repository